Published in Circulation on December 09, 2014
Systematic study of constitutive cyclooxygenase-2 expression: Role of NF-κB and NFAT transcriptional pathways. Proc Natl Acad Sci U S A (2015) 0.82
Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival. Oncotarget (2016) 0.80
Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol (2016) 0.77
Reply to Letter Regarding Article, "Evidence That Links Loss of Cyclooxygenase-2 With Increased Asymmetric Dimethylarginine: Novel Explanation of Cardiovascular Side Effects Associated With Anti-Inflammatory Drugs". Circulation (2015) 0.77
Ibuprofen arginate retains eNOS substrate activity and reverses endothelial dysfunction: implications for the COX-2/ADMA axis. FASEB J (2016) 0.75
Metabolomic Profiling of Arginine Metabolome Links Altered Methylation to Chronic Kidney Disease Accelerated Atherosclerosis. J Proteomics Bioinform (2015) 0.75
Metabolomic profiling of amines in sepsis predicts changes in NOS canonical pathways. PLoS One (2017) 0.75
Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46
Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A (1989) 8.34
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A (1999) 5.96
Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature (1995) 3.44
Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med (2007) 3.28
Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation (2007) 3.27
The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase. J Biol Chem (1996) 3.04
Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation (1999) 2.77
Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med (2011) 2.64
Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest (1994) 2.55
NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology (2000) 2.43
Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol (2003) 2.29
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther (1999) 2.10
Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation (1998) 2.08
Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation (2009) 2.05
Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem (2006) 2.01
Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest (2002) 1.86
Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev (2008) 1.82
COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol (2007) 1.77
Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med (2012) 1.71
Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int (2002) 1.69
Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol (1999) 1.65
Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol (1999) 1.65
Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol (1997) 1.45
Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci U S A (2009) 1.41
Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol (2001) 1.40
Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med (1985) 1.39
Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A (2012) 1.35
COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet (2008) 1.29
Renal effects of cyclooxygyenase-2-selective inhibitors. J Pain Symptom Manage (2002) 1.20
Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators? Arterioscler Thromb Vasc Biol (2012) 1.19
Cyclooxygenase in normal human tissues--is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J Cell Mol Med (2008) 1.18
Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol (2001) 1.12
Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries. Exp Physiol (2011) 1.07
Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. J Biol Chem (2009) 1.02
Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2. J Mol Cell Cardiol (2010) 0.99
Prostacyclin mediates neuropathic pain through interleukin 1β-expressing resident macrophages. Pain (2013) 0.95
L-glutamine inhibits the release of endothelium-derived relaxing factor from the rabbit aorta. Biochem Biophys Res Commun (1990) 0.95
Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol (2002) 0.94
The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol Rev (2011) 0.89
LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression. PLoS One (2013) 0.88
Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis (2001) 0.87
Physiologic and pathophysiologic roles of cyclooxygenase-2 in the kidney. Trans Am Clin Climatol Assoc (2013) 0.87
Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide. Proc Natl Acad Sci U S A (2013) 0.86
COX-2 and the kidneys. Curr Pharm Des (2000) 0.86
NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. Am J Med (2013) 0.82
Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies. Expert Opin Drug Saf (2014) 0.81
Plasma concentration of asymmetric dimethylarginine and the risk of coronary heart disease: rationale and design of the multicenter CARDIAC study. Atheroscler Suppl (2003) 0.81